Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. It operates through three segments: Concordia International, Concordia North America, and Orphan Drugs. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segments products include Tetroxin drug for severe hypothyroid states; Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; and Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria; and Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy. The Orphan Drugs segment develops Photofrin, a light-based cancer treatment that combines a photosensitizing drug called porfimer sodium with a specific type of light to attack cancer cells. The company sells through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: TSE:CXR
- CUSIP: N/A
- Web: concordiarx.com
Capitalization:- Market Cap: C$80.72 million
- Outstanding Shares: 51,089,000
Average Prices:- 50 Day Moving Avg: C$1.86
- 200 Day Moving Avg: C$2.16
- 52 Week Range: C$1.41 - C$12.46
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: C$748.18 million
- Price / Sales: 0.11
- Book Value: C($8.59) per share
- Price / Book: -0.18
Profitability:- EBIDTA: C$380.7 million
- Net Margins: -49.09%
- Return on Assets: -8.60%
Misc:- Average Volume: 229,259 shs.
- Short Ratio: 0.8
Frequently Asked Questions for Concordia International Corp (TSE:CXR)
What is Concordia International Corp's stock symbol?
Concordia International Corp trades on the Tornton Stock Exchange (TSX) under the ticker symbol "CXR."
How were Concordia International Corp's earnings last quarter?
Concordia International Corp (TSE:CXR) announced its quarterly earnings data on Thursday, August, 13th. The company reported $1.04 EPS for the quarter, missing analysts' consensus estimates of $1.06 by $0.02. The company earned $95.34 million during the quarter, compared to analyst estimates of $87.41 million. View Concordia International Corp's Earnings History.
When will Concordia International Corp make its next earnings announcement?
Where is Concordia International Corp's stock going? Where will Concordia International Corp's stock price be in 2017?
4 equities research analysts have issued 1-year price targets for Concordia International Corp's stock. Their predictions range from C$13.50 to C$14.00. On average, they anticipate Concordia International Corp's share price to reach C$13.75 in the next year. View Analyst Ratings for Concordia International Corp.
Who are some of Concordia International Corp's key competitors?
Some companies that are related to Concordia International Corp include VBI Vaccines (VBIV), Mirati Therapeutics (MRTX), ContraFect Corporation (CFRX), XOMA Corporation (XOMA), Aevi Genomic Medicine (GNMX), Trillium Therapeutics (TRIL), Ohr Pharmaceuticals (OHRP), Humanigen (KBIO), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN) and DNIB Unwind (BIND).
Who are Concordia International Corp's key executives?
Concordia International Corp's management team includes the folowing people:
- Jordan M. Kupinsky J.D., Chairman of the Board
- Wayne Kreppner, President, Chief Operating Officer
- Allan Oberman, Chief Executive Officer, Director
- David J. Price, Chief Financial Officer
- Graeme Duncan, President - Company's International Segment
- Arijit Mookerjee, Managing Director, Chief Financial Officer - Operations
- Adeel Ahmad, Chief Financial Officer of AMCo
- Francesco Tallarico, Chief Legal Officer and Secretary
- Patrick Vink M.D., Director
- Douglas N. Deeth, Independent Director
How do I buy Concordia International Corp stock?
Shares of Concordia International Corp and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Concordia International Corp's stock price today?
One share of Concordia International Corp stock can currently be purchased for approximately C$1.58.
MarketBeat Community Rating for Concordia International Corp (TSE CXR)MarketBeat's community ratings are surveys of what our community members think about Concordia International Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Concordia International Corp (TSE:CXR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Sell Ratings |
| Consensus Rating: | Sell (Score: 1.00) |
| Consensus Price Target: | C$13.75 |
Analysts' Ratings History for Concordia International Corp (TSE:CXR)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 3/16/2017 | Scotiabank | Reiterated Rating | Underperform | |  |
| 2/9/2017 | TD Securities | Downgrade | Hold -> Reduce | | |
| 12/8/2016 | Royal Bank Of Canada | Downgrade | Sector Perform -> Underperform | | |
| 11/7/2016 | Bloom Burton | Downgrade | Hold -> Sell | | |
| 8/15/2016 | Goldman Sachs Group, Inc. (The) | Lower Price Target | | C$34.00 -> C$17.00 | |
| 8/15/2016 | CIBC | Downgrade | Sector Perform -> Underperform | | |
| 3/21/2016 | Dundee Securities | Lower Price Target | | C$62.00 -> C$60.00 | |
| 12/3/2015 | Mackie | Downgrade | Hold | | |
| 9/9/2015 | Canaccord Genuity | Boost Price Target | | C$95.00 -> C$100.00 | |
(Data available from 8/17/2015 forward)
Earnings History for Concordia International Corp (TSE:CXR)Earnings History by Quarter for Concordia International Corp (TSE CXR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | | | | | | | |
| 8/13/2015 | Q2 | $1.06 | $1.04 | $87.41 million | $95.34 million | View | Listen | |
| 8/13/2014 | | $0.19 | ($0.03) | $24.42 million | $28.49 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Concordia International Corp (TSE:CXR)Current Year EPS Consensus Estimate: $0.80 EPS
Dividend History by Quarter for Concordia International Corp (TSE CXR)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/13/2016 | Quarterly | $0.08 | 1.14% | 7/13/2016 | 7/29/2016 | 7/29/2016 |
| 4/13/2016 | Quarterly | $0.08 | 0.95% | 4/13/2016 | 4/29/2016 | 4/29/2016 |
| 1/13/2016 | Quarterly | $0.08 | 0.53% | 1/13/2016 | 1/29/2016 | 1/29/2016 |
| 10/13/2015 | Quarterly | $0.08 | 0.62% | 10/13/2015 | 10/30/2015 | 10/30/2015 |
| 7/13/2015 | Quarterly | $0.08 | 0.32% | 7/13/2015 | 7/31/2015 | 7/31/2015 |
| 4/13/2015 | Quarterly | $0.08 | 0.35% | 4/13/2015 | 4/30/2015 | 4/30/2015 |
| 1/13/2015 | Quarterly | $0.08 | 0.61% | 1/13/2015 | 1/31/2015 | 1/31/2015 |
| 10/10/2014 | Quarterly | $0.08 | 0.76% | 10/10/2014 | 10/31/2014 | 10/31/2014 |
| 7/11/2014 | Quarterly | $0.08 | 0.92% | 7/11/2014 | 7/31/2014 | 7/31/2014 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Concordia International Corp (TSE:CXR)Insider Trades by Quarter for Concordia International Corp (TSE:CXR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/25/2017 | Erin Colleen O'neil | Director | Sell | 191 | C$1.74 | C$332.34 | |
| 5/16/2017 | Graeme Neville Duncan | Director | Sell | 7,065 | C$1.91 | C$13,494.15 | |
| 2/1/2016 | Mark Laurence Thompson | Director | Buy | 60 | C$28.77 | C$1,726.20 | |
| 11/17/2015 | Rochelle Fuhrmann | Director | Buy | 2,000 | C$31.67 | C$63,340.00 | |
| 11/17/2015 | Wayne Walter Kreppner | Insider | Buy | 3,000 | C$43.67 | C$131,010.00 | |
| 11/16/2015 | Mark Laurence Thompson | Director | Buy | 23,150 | C$43.36 | C$1,003,702.98 | |
| 10/27/2015 | Edward Borkowski | Director | Buy | 4,000 | C$30.43 | C$121,720.00 | |
| 7/23/2015 | Jordan Kupinsky | Director | Sell | 43,000 | C$103.70 | C$4,459,272.00 | |
| 7/17/2015 | Wayne Walter Kreppner | Insider | Sell | 4,800 | C$103.00 | C$494,400.00 | |
| 7/3/2015 | Jordan Kupinsky | Director | Sell | 10,800 | C$92.21 | C$995,884.20 | |
| 7/2/2015 | Jordan Kupinsky | Director | Sell | 45,900 | C$92.05 | C$4,224,934.35 | |
| 6/26/2015 | Robert Steven Altman | Insider | Sell | 62,500 | C$93.93 | C$5,870,893.75 | |
| 6/22/2015 | John-Michel Huss | Director | Sell | 5,000 | C$92.00 | C$460,000.00 | |
| 6/19/2015 | John-Michel Huss | Director | Sell | 4,300 | C$90.00 | C$387,000.00 | |
| 6/11/2015 | John-Michel Huss | Director | Sell | 4,500 | C$90.02 | C$405,076.50 | |
| 5/27/2015 | Saldanha Adrian De | Insider | Buy | 1,000 | C$80.61 | C$80,610.00 | |
| 5/19/2015 | Adeel Ahmad | Insider | Sell | 25,000 | C$83.80 | C$2,094,890.00 | |
| 10/31/2014 | James Christopher Reebals | Director | Sell | 7,500 | C$37.25 | C$279,360.75 | |
| 10/30/2014 | James Christopher Reebals | Director | Sell | 7,500 | C$37.06 | C$277,926.75 | |
| 10/29/2014 | James Christopher Reebals | Director | Sell | 5,000 | C$37.07 | C$185,336.50 | |
(Data available from 1/1/2013 forward)
Headline Trends for Concordia International Corp (TSE:CXR)
Latest Headlines for Concordia International Corp (TSE:CXR)
| Source: |
|
Concordia International Corp (CXR) Chart for Thursday, August, 17, 2017
